Diffuse Large B Cell Lymphoma Therapeutic

Diffuse large B-cell lymphoma (DLBCL) is the most common lymphoid malignancy and accounts for the majority of aggressive non-Hodgkin lymphoma cases in the US.   While it is a curable disease with significant success from rituximab and CHOP chemotherapeutic treatment, a significant minority of patients with advanced stage disease and clinical risk factors are in need of alternative treatment strategies.Scientists at NCI ’sLymphoid Malignancies Branch, have developed a novel stapled-peptide that specifically targets the linear polyubiquitin chain assembly complex (LUBAC), a pathway involved in NF- κB activation via binding of two protein molecules, RNF31 and RBCK1.  The investigators have genetic, biochemical and functional evidence showing that the These cell-permeable peptides compete against endogenous RNF31, therefore inhibit the NF-kB induction pathway and kill the malignant cells.IC: NCINIH Ref. No.: E-035-2013Advantages: - Novel composition of inhibitors for advance stage ABC DLBCL,  Effective therapies targeting at NF-kB pathway, Novel therapeutic for ABC DLBCL not responsive to rituximab and CHOP chemotherapy.Applications: - Targeted therapies for ABC DLBCL. - Combination cytotoxic chemotherapies for ABC DLBCL. - Treatment for other cancers or  autoimmune/inflammatory diseases that depend upon the function of RNF31 and RBCK1 combination.Development Status: Discovery (Lead Identification)Updated On: Mar 29, 2018Provider Classifica...
Source: NIH OTT Licensing Opportunities - Category: Research Authors: Source Type: research